Natasha Bagdasarian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Natasha Bagdasarian has a total of 153 co-authors. Here are the top co-authors by number of shared publications:
Dale Fisher
National University Hospital, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore
3 shared publicationsKrishna Rao
Department of Internal Medicine, University of Michigan Health System, Ann Arbor
3 shared publications- Paul Anantharajah Tambyah
National University Hospital
3 shared publications Preeti N. Malani
Department of Internal Medicine, University of Michigan Health System, Ann Arbor3Associate Editor, JAMA
3 shared publicationsD. Fisher
Division of Infectious Diseases, Department of Medicine, National University Hospital, Singapore, Singapore
2 shared publications- Dale Fisher
Division of Infectious Diseases, Department of Medicine, National University Health System, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore
2 shared publications
Latest Publications
- 10 July 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Watching the Ship, Missing the Forest: Why Ecological Spillover, Reservoir Ecology, and Environmental Change Remain the True Hantavirus Threats in North America
Hantavirus emergence in North America is driven by interactions among reservoir ecology, environmental variability, landscape conditions, and human exposure, with ongoing environmental change increasing spillover opportunities, altering the geography of risk, and challenging traditional public health surveillance systems.
- 10 July 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
Watching the Ship, Missing the Forest: Why Ecological Spillover, Reservoir Ecology, and Environmental Change Remain the True Hantavirus Threats in North America
Hantavirus emergence in North America is driven by interactions among reservoir ecology, environmental variability, landscape conditions, and human exposure, with ongoing environmental change increasing spillover opportunities, altering the geography of risk, and challenging traditional public health surveillance systems.
- Open Access
- 30 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (4)
Containment of a Multi-index B.1.1.7 Outbreak on a University Campus Through a Genomically Informed Public Health Response
Increasing the precision of outbreak containment for emerging virus strains requires real-time virus identification that can be integrated with specific public health actions. During the SARS-CoV-2 pandemic, we established a multisector partnership to support rapid genomically informed containment response. This system was in place prior to emergence of the first cluster of SARS-CoV-2 cases with lineage B.1.1.7 in the state of Michigan, which was identified through intensive university-led surveillance sampling and rapid, targeted sequencing. Sequencing data were integrated in real time with a collaborative investigation and response led by the local and state health departments, with university and athletic medicine COVID-19 response teams. In this response, subsequent sampling and just-in-time sequencing were specifically directed toward first- and second-order contacts of B.1.1.7 cases. A total of 50 cases of B.1.1.7-lineage SARS-CoV-2 were identified in this outbreak, which was due to 3 coincident introductions of B.1.1.7-lineage SARS-CoV-2 in the background of a large number of non-B.1.1.7 cases. This initial outbreak was contained, as all subsequent B.1.1.7 infections in the university and surrounding community were due to genetically distinct lineages. This investigation demonstrates the successful implementation of a genomically informed outbreak response that can be extended to university campuses and other settings at high risk for rapid emergence of new viruses or viral variants.
- 30 March 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (4)
Open AccessContainment of a Multi-index B.1.1.7 Outbreak on a University Campus Through a Genomically Informed Public Health Response
Increasing the precision of outbreak containment for emerging virus strains requires real-time virus identification that can be integrated with specific public health actions. During the SARS-CoV-2 pandemic, we established a multisector partnership to support rapid genomically informed containment response. This system was in place prior to emergence of the first cluster of SARS-CoV-2 cases with lineage B.1.1.7 in the state of Michigan, which was identified through intensive university-led surveillance sampling and rapid, targeted sequencing. Sequencing data were integrated in real time with a collaborative investigation and response led by the local and state health departments, with university and athletic medicine COVID-19 response teams. In this response, subsequent sampling and just-in-time sequencing were specifically directed toward first- and second-order contacts of B.1.1.7 cases. A total of 50 cases of B.1.1.7-lineage SARS-CoV-2 were identified in this outbreak, which was due to 3 coincident introductions of B.1.1.7-lineage SARS-CoV-2 in the background of a large number of non-B.1.1.7 cases. This initial outbreak was contained, as all subsequent B.1.1.7 infections in the university and surrounding community were due to genetically distinct lineages. This investigation demonstrates the successful implementation of a genomically informed outbreak response that can be extended to university campuses and other settings at high risk for rapid emergence of new viruses or viral variants.
- Open Access
- 3 June 2025
- Published by Wiley in Journal of Hospital Medicine
- Vol. 20 (7) , 787-790
Rebuilding trust in public health and medicine in a time of declining trust in science
Trust in public health and medical practitioners has declined since COVID‐19. Throughout the COVID‐19 pandemic, poor communication by medical and public health professionals coincident with the rise of social media enabled unverified, often erroneous information to spread quickly and widely. Providing accurate, fact‐based information is imperative to save lives and promote health. Using a robust, evidence‐based approach to tracking the spread of information and partnering with trusted messengers, states can take a leadership role in combatting misinformation and safeguarding the public's health.
- 3 June 2025
- Published by Wiley in Journal of Hospital Medicine
- Vol. 20 (7) , 787-790
Open AccessRebuilding trust in public health and medicine in a time of declining trust in science
Trust in public health and medical practitioners has declined since COVID‐19. Throughout the COVID‐19 pandemic, poor communication by medical and public health professionals coincident with the rise of social media enabled unverified, often erroneous information to spread quickly and widely. Providing accurate, fact‐based information is imperative to save lives and promote health. Using a robust, evidence‐based approach to tracking the spread of information and partnering with trusted messengers, states can take a leadership role in combatting misinformation and safeguarding the public's health.
- 15 September 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (3) , 543-544
Personal Protective Equipment Guidance for Highly Pathogenic Avian Influenza H5N1 Should Be Adapted to Meet the Needs of Dairy Farm Workers
- 15 September 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (3) , 543-544
Personal Protective Equipment Guidance for Highly Pathogenic Avian Influenza H5N1 Should Be Adapted to Meet the Needs of Dairy Farm Workers
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1764. Collaboration between Public Health and Healthcare Partners to Attack the Rising Menace of Candida auris: The Michigan Experience
Candida auris is an emerging fungal pathogen with high rates of morbidity and mortality. In May 2021, the Michigan Department of Health and Human Services (MDHHS), detected its first case of Candida auris and has since seen a rapid increase in southeast MI. There is currently no C. auris screening guidance developed for states. MDHHS Surveillance for Healthcare Associated and Resistant Pathogens (SHARP) Unit convened a multidisciplinary group from acute care facilities to collaborate on the development of guidance to rapidly assess, screen, and isolate patients entering healthcare facilities in efforts to slow the spread of C. auris. The MDHHS SHARP Unit invited individuals representing infection prevention, infectious diseases, antimicrobial stewardship/pharmacy, lab, and epidemiology to participate. The purpose was to engage healthcare partners by providing updates on epidemiology, surveillance, antifungal susceptibilities, lab capacity, and containment/prevention activities in the state. Facilities were able to share best-practices and collaborate with public health to develop pragmatic recommendations that could be implemented within facilities across the region. MDHHS collaborated with healthcare partners to develop C. auris screening guidance that is evidence-based, easy-to-reference, and adaptable across facility-types. Previous regional approaches, such as the Michigan CRE Surveillance and Prevention Initiative, have proven to be substantially more effective at stemming the spread of multidrug resistant organisms. Michigan will continue these successful collaborations and apply this approach for future emerging pathogens. jason M. Pogue, PharmD, AbbVie: Advisor/Consultant|Entasis: Advisor/Consultant|Ferring: Advisor/Consultant|GSK: Advisor/Consultant|Merck: Advisor/Consultant|Merck: Grant/Research Support|Qpex: Advisor/Consultant|Shionogi: Advisor/Consultant
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1764. Collaboration between Public Health and Healthcare Partners to Attack the Rising Menace of Candida auris: The Michigan Experience
Candida auris is an emerging fungal pathogen with high rates of morbidity and mortality. In May 2021, the Michigan Department of Health and Human Services (MDHHS), detected its first case of Candida auris and has since seen a rapid increase in southeast MI. There is currently no C. auris screening guidance developed for states. MDHHS Surveillance for Healthcare Associated and Resistant Pathogens (SHARP) Unit convened a multidisciplinary group from acute care facilities to collaborate on the development of guidance to rapidly assess, screen, and isolate patients entering healthcare facilities in efforts to slow the spread of C. auris. The MDHHS SHARP Unit invited individuals representing infection prevention, infectious diseases, antimicrobial stewardship/pharmacy, lab, and epidemiology to participate. The purpose was to engage healthcare partners by providing updates on epidemiology, surveillance, antifungal susceptibilities, lab capacity, and containment/prevention activities in the state. Facilities were able to share best-practices and collaborate with public health to develop pragmatic recommendations that could be implemented within facilities across the region. MDHHS collaborated with healthcare partners to develop C. auris screening guidance that is evidence-based, easy-to-reference, and adaptable across facility-types. Previous regional approaches, such as the Michigan CRE Surveillance and Prevention Initiative, have proven to be substantially more effective at stemming the spread of multidrug resistant organisms. Michigan will continue these successful collaborations and apply this approach for future emerging pathogens. jason M. Pogue, PharmD, AbbVie: Advisor/Consultant|Entasis: Advisor/Consultant|Ferring: Advisor/Consultant|GSK: Advisor/Consultant|Merck: Advisor/Consultant|Merck: Grant/Research Support|Qpex: Advisor/Consultant|Shionogi: Advisor/Consultant
- Open Access
- 12 March 2022
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (6) , 2460-2470
Discrepant serological findings in SARS‐CoV‐2 PCR‐negative hospitalized patients with fever and acute respiratory symptoms during the pandemic
Background COVID-19 serology has an evolving role in the diagnosis of SARS-CoV-2 infection. However, its use in hospitalised patients with acute respiratory symptoms remains unclear. Methods Hospitalised patients with acute respiratory illness admitted to an isolation ward were recruited. All patients had negative nasopharyngeal swab polymerase chain reaction (PCR) for SARS-CoV-2. Serological studies using 4 separate assays (cPass: surrogate neutralising ELISA; Elecsys: N-antigen based chemiluminescent assay; SFB: S protein flow-based; epitope peptide-based ELISA;) were performed on stored plasma collected from patients during the initial hospital stay, and a convalescent visit 4-12 weeks later. Results Of the 51 patients studied (aged 54, IQR 21-84; 62.7% male), no patients tested positive on the Elecsys or cPass assays. 5/51 patients had antibodies detected on B-cell Epitope Assay, and 3/51 had antibodies detected on SFB assay. These 8 patients with positive serological test to COVID-19 were more likely to have a high-risk occupation (p=0.039), bacterial infection (p=0.028) and neutrophilia (p=0.013) during their initial hospital admission. Conclusion Discrepant COVID-19 serological findings were observed amongst those with recent hospital admissions and bacterial infections. The positive serological findings within our cohort raise important questions about the interpretation of sero-epidemiology during the current pandemic.
- 12 March 2022
- Published by Wiley in Journal of Medical Virology
- Vol. 94 (6) , 2460-2470
Open AccessDiscrepant serological findings in SARS‐CoV‐2 PCR‐negative hospitalized patients with fever and acute respiratory symptoms during the pandemic
Background COVID-19 serology has an evolving role in the diagnosis of SARS-CoV-2 infection. However, its use in hospitalised patients with acute respiratory symptoms remains unclear. Methods Hospitalised patients with acute respiratory illness admitted to an isolation ward were recruited. All patients had negative nasopharyngeal swab polymerase chain reaction (PCR) for SARS-CoV-2. Serological studies using 4 separate assays (cPass: surrogate neutralising ELISA; Elecsys: N-antigen based chemiluminescent assay; SFB: S protein flow-based; epitope peptide-based ELISA;) were performed on stored plasma collected from patients during the initial hospital stay, and a convalescent visit 4-12 weeks later. Results Of the 51 patients studied (aged 54, IQR 21-84; 62.7% male), no patients tested positive on the Elecsys or cPass assays. 5/51 patients had antibodies detected on B-cell Epitope Assay, and 3/51 had antibodies detected on SFB assay. These 8 patients with positive serological test to COVID-19 were more likely to have a high-risk occupation (p=0.039), bacterial infection (p=0.028) and neutrophilia (p=0.013) during their initial hospital admission. Conclusion Discrepant COVID-19 serological findings were observed amongst those with recent hospital admissions and bacterial infections. The positive serological findings within our cohort raise important questions about the interpretation of sero-epidemiology during the current pandemic.
- Open Access
- 1 February 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 103, 389-394
SARS-CoV-2 in migrant worker dormitories: Geospatial epidemiology supporting outbreak management
- 1 February 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 103, 389-394
Open AccessSARS-CoV-2 in migrant worker dormitories: Geospatial epidemiology supporting outbreak management
- Open Access
- 25 June 2020
- Published by Springer Nature in BMC Medicine
- Vol. 18 (1) , 1-5
Rapid publications risk the integrity of science in the era of COVID-19
Background: Preprint manuscripts, rapid publications and opinion pieces have been essential in permitting the lay press and public health authorities to preview data relating to coronavirus disease 2019 (COVID-19), including the range of clinical manifestations and the basic epidemiology early on in the pandemic. However, the rapid dissemination of information has highlighted some issues with communication of scientific results and opinions in this time of heightened sensitivity and global concern. Main text: Rapid publication of COVID-19 literature through expedited review, preprint publications and opinion pieces are important resources for the medical scientific community. Yet the risks of unverified information loom large in times when the healthcare community is desperate for information. Information that has not been properly vetted, or opinion pieces without solid evidence, may be used to influence public health policy decisions. We discuss three examples of unverified information and the consequences in this time of high anxiety surrounding COVID-19. Conclusions: In an era when information can be widely and swiftly disseminated, it is important to ensure that the scientific community is not an inadvertent source of misinformation. This will require a multimodal approach, with buy-in from editors, publishers, preprint servers, authors and journalists. The landscape of medical publications has changed, and a collaborative approach is required to maintain a high standard of scientific communications.
- 25 June 2020
- Published by Springer Nature in BMC Medicine
- Vol. 18 (1) , 1-5
Open AccessRapid publications risk the integrity of science in the era of COVID-19
Background: Preprint manuscripts, rapid publications and opinion pieces have been essential in permitting the lay press and public health authorities to preview data relating to coronavirus disease 2019 (COVID-19), including the range of clinical manifestations and the basic epidemiology early on in the pandemic. However, the rapid dissemination of information has highlighted some issues with communication of scientific results and opinions in this time of heightened sensitivity and global concern. Main text: Rapid publication of COVID-19 literature through expedited review, preprint publications and opinion pieces are important resources for the medical scientific community. Yet the risks of unverified information loom large in times when the healthcare community is desperate for information. Information that has not been properly vetted, or opinion pieces without solid evidence, may be used to influence public health policy decisions. We discuss three examples of unverified information and the consequences in this time of high anxiety surrounding COVID-19. Conclusions: In an era when information can be widely and swiftly disseminated, it is important to ensure that the scientific community is not an inadvertent source of misinformation. This will require a multimodal approach, with buy-in from editors, publishers, preprint servers, authors and journalists. The landscape of medical publications has changed, and a collaborative approach is required to maintain a high standard of scientific communications.
- Open Access
- 24 June 2020
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 42 (5) , 630-632
A safe and efficient, naturally ventilated structure for COVID-19 surge capacity in Singapore
- 24 June 2020
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 42 (5) , 630-632
Open AccessA safe and efficient, naturally ventilated structure for COVID-19 surge capacity in Singapore
- Open Access
- 10 June 2020
- Published by MDPI AG in Antibiotics
- Vol. 9 (6) , 316
A Prediction Tool for the Presence of Ceftriaxone-Resistant Uropathogens upon Hospital Admission
Antimicrobial resistance among uropathogens is a particularly pressing problem in the Asia-Pacific region. The objectives of this study were to determine the incidence and susceptibility of uropathogens upon hospital admission and to develop a risk-scoring model to predict the presence of ceftriaxone-resistance uropathogens (CrP). This was a retrospective observational cohort study of patients with a positive urine culture within 48 h of presentation at National University Hospital, Singapore between June 2015 and August 2015. Escherichia coli was the most common uropathogen isolated (51.7%), followed by Klebsiella pneumonia (15.1%) and Pseudomonas aeruginosa (8.2%). Overall, 372 out of 869 isolates (42.8%) were resistant to ceftriaxone. Hospitalization for ≥2 days within past 30 days, antibiotic use within the past 3 months and male gender were associated with the presence of CrP. A risk score based on these parameters successfully predicted CrP with an area under the curve of 0.68. The risk score will help clinicians to accurately predict antibiotic resistance at the individual patient level and allow physicians to safely prescribe empiric ceftriaxone in patients at low risk of CrP, thus reducing the antibiotic selection pressure that is driving carbapenem resistance in hospitals throughout Asia.
- 10 June 2020
- Published by MDPI AG in Antibiotics
- Vol. 9 (6) , 316
Open AccessA Prediction Tool for the Presence of Ceftriaxone-Resistant Uropathogens upon Hospital Admission
Antimicrobial resistance among uropathogens is a particularly pressing problem in the Asia-Pacific region. The objectives of this study were to determine the incidence and susceptibility of uropathogens upon hospital admission and to develop a risk-scoring model to predict the presence of ceftriaxone-resistance uropathogens (CrP). This was a retrospective observational cohort study of patients with a positive urine culture within 48 h of presentation at National University Hospital, Singapore between June 2015 and August 2015. Escherichia coli was the most common uropathogen isolated (51.7%), followed by Klebsiella pneumonia (15.1%) and Pseudomonas aeruginosa (8.2%). Overall, 372 out of 869 isolates (42.8%) were resistant to ceftriaxone. Hospitalization for ≥2 days within past 30 days, antibiotic use within the past 3 months and male gender were associated with the presence of CrP. A risk score based on these parameters successfully predicted CrP with an area under the curve of 0.68. The risk score will help clinicians to accurately predict antibiotic resistance at the individual patient level and allow physicians to safely prescribe empiric ceftriaxone in patients at low risk of CrP, thus reducing the antibiotic selection pressure that is driving carbapenem resistance in hospitals throughout Asia.